ABBV vs NFLX: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Netflix, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-17.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Netflix, Inc. · Communication Services
$76.41
+44.0% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
NFLX has more upside to fair value
(+44.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
NFLX |
| Current Price |
$261.70 |
$76.41 |
| Fair Value Estimate |
$259.04 |
$110.00 |
| Upside to Fair Value |
-1.0%
|
+44.0%
|
| Market Cap |
$462.4B |
$318.2B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
10.6x
|
| Price / Sales |
7.2x
|
6.6x
|
| Price / FCF |
23.6x
|
29.1x
|
| Revenue Growth YoY |
+10.2%
|
+13.4%
|
| Gross Margin |
71.5%
|
49.1%
|
| Operating Margin |
29.3%
|
29.7%
|
| Return on Equity |
-136.5%
|
48.0%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
3.44%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Netflix is a global subscription and advertising-supported entertainment platform with a high-quality brand, content engine, recommendation technology and distribution scale, evidenced by more than 97 billion viewing hours in the first half of 2026 and an audience approaching one billion people. Fundamentals remain strong: revenue grew 13.4% year over year in the most recent quarter, TTM gross, o…
Accumulation Zones
| Metric |
ABBV |
NFLX |
| Zone Low |
$194.28 |
$82.50 |
| Zone High |
$220.18 |
$93.50 |
| In Buy Zone? |
No
|
Yes
|